• Skip to main content
  • Skip to navigation
Site name
Site name
Mast navigation
  • Become a member
  • Sign In
Search our site
Menu
Close menu
  • Home
  • News
  • Bioprocessing
  • QA
  • Topics
    • Back to parent navigation item
    • Topics
    • Analytical and bioanalysis
    • Bioprocessing and biomanufacturing
    • Quality, microbiology and contamination control
    • Regulation and compliance
    • Formulation and drug delivery
    • Packaging, containers and labelling
    • Digital and Pharma 4.0
  • Webinars
  • Reports
  • Publications
  • Future of Bio/Pharma 2026
  • Knowledge Hub
  • Home
  • News
  • Bioprocessing
  • QA
  • Topics
      • Analytical and bioanalysis
      • Bioprocessing and biomanufacturing
      • Quality, microbiology and contamination control
      • Regulation and compliance
      • Formulation and drug delivery
      • Packaging, containers and labelling
      • Digital and Pharma 4.0
    • jakarta-march-united-drug-fda
      FDA seeks feedback on new framework for rare disease drug development
    • AstraZeneca logo
      AstraZeneca commits $2bn to advance ADC combination medicines for cancer
    • novo nordisk logo
      Novo Nordisk tightens obesity market focus with ‘Novo’ name change
  • Webinars
  • Reports
  • Publications
  • Future of Bio/Pharma 2026
  • Knowledge Hub
  • More navigation items

Scaling complex cell therapies from clinical to commercial : References

2026-04-10T19:16:00+01:00

  • No comments

Reference links and supporting resources for ”Scaling complex cell therapies from clinical to commercial”

 

References 

  1. Flexible Requirements For Cell And Gene Therapies To Advance Innovation [Internet] FDA. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation 

  1. ICH Q10 Pharmaceutical Quality System. [Internet] International Council for Harmonisation (ICH). 2008. Available from: https://database.ich.org/sites/default/files/Q10%20Guideline.pdf 

  1. EudraLex Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use: Annex 1 — Manufacture of Sterile Medicinal Products. Brussels: European Commission. 2022. Available from: https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf 

  • No comments

No comments yet

You're not signed in.

Only registered users can comment on this article.

Sign in Register

Partner content

  • AdobeStock_2090265110 (1)
    Article

    Choosing an endotoxin method in the recombinant era

    2026-09-28T12:37:00

    Sponsored by Charles River Laboratories

  • DV_PSM1
    Webinar

    Realising autonomous pharmaceutical operations

    2026-02-09T10:00:00

    Sponsored by Emerson

  • map concept pills
    Article

    Medicines as strategic assets: the new politics of pharma supply

    2026-05-22T14:48:00

    Sponsored by CPhI

  • FX 500
    Article

    FLEX-500 - all-in-one serialization

    2026-09-28T12:35:00

    Sponsored by AGE OTOMASYON

  • 12_PCI-DMMaster-Blend-v3-1 (2)
    Article

    Precision control for target protein degraders

    2026-09-10T09:00:00

    Sponsored by PCI Pharma Services, David O’Connell

  • CTA Image
    Article

    Selecting the right qPCR workflow strategy: task-based vs. full automation

    2026-06-01T08:21:00

    Sponsored by Gilson

  • Topics
  • Analytical and bioanalysis
  • Bioprocessing and biomanufacturing
  • Quality, microbiology and contamination control
  • Regulation and compliance
  • Formulation and drug delivery
  • Packaging, containers and labelling
  • Advertising & Editorial
  • Advertising opportunities
  • Media planner
  • Advisory board
  • Information for authors
  • Reuse policy
  • Information
  • About us
  • Company information
  • Careers
  • Terms and conditions
  • Privacy policy
  • Cookie policy
Leading the conversation in pharma manufacturing
Find us on social media:
  • Topics A-Z
  • Writers A-Z
  • © 2026 European Pharmaceutical Review

Site powered by Webvision Cloud